Sushil Patel Sells 10,000 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Replimune Group Trading Up 3.0 %

NASDAQ REPL opened at $12.01 on Friday. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock’s 50 day moving average price is $12.23 and its two-hundred day moving average price is $10.64. The stock has a market capitalization of $821.69 million, a price-to-earnings ratio of -3.94 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, analysts anticipate that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on REPL. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. BMO Capital Markets lifted their price objective on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. JPMorgan Chase & Co. boosted their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Replimune Group in a report on Friday, November 22nd. Finally, Jefferies Financial Group lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Replimune Group currently has an average rating of “Buy” and a consensus price target of $17.29.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP boosted its stake in shares of Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after buying an additional 1,000,000 shares during the last quarter. Millennium Management LLC increased its position in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Braidwell LP raised its holdings in Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after acquiring an additional 2,057,460 shares in the last quarter. State Street Corp boosted its position in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after purchasing an additional 217,308 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.